Inhibition of Insulin-Like Growth Factor-1–Induced Sebum Production by Bilobetin in Cultured Human Sebocytes
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Sebocytes are the major cells of sebaceous gland. The essential role of sebocytes is the production of sebum, a specific lipid mixture, that covers the body surface and provides the barrier function. At puberty, sebum production increases under the effects of various stimuli including androgens and insulin-like growth factor-1 (IGF-1). Excessive sebum production changes the microenvironment surrounding hair follicle, often leading to the onset of acne. Objective: We previously performed screening test using cultured human sebocytes, and found that bilobetin had a potential for inhibiting lipid production. The aim of this study is to demonstrate the effects of bilobetin on IGF-1–induced lipogenesis in sebocytes. Methods: We pretreated simian virus 40 T (SV40T)-transformed sebocytes with bilobetin then stimulated with IGF-1. Effects of bilobetin on lipogenesis of sebocytes were examined by thin layer chromatography and Western blot. Results: Bilobetin markedly inhibited IGF-1– induced lipid production in sebocytes, especially in terms of production of squalene and wax ester. Supporting these results, bilobetin showed significant inhibitory effect on squalene synthase promoter activity. In addition, bilobetin significantly down-regulated lipogenic transcription factors such as sterol response element binding protein (SREBP)-1 and SREBP-2. To delineate the possible action mechanism, we investigated the effect of bilobetin on intracellular signaling. As a result, bilobetin inhibited IGF-1–induced phosphorylation of AKT. Conclusion: Together, these results suggest that bilobetin has an inhibitory potential on sebum production in sebocytes, being applicable for acne treatment.
Abstract
Background: Sebocytes are the major cells of sebaceous gland. The essential role of sebocytes is the production of sebum, a specific lipid mixture, that covers the body surface and provides the barrier function. At puberty, sebum production increases under the effects of various stimuli including androgens and insulin-like growth factor-1 (IGF-1). Excessive sebum production changes the microenvironment surrounding hair follicle, often leading to the onset of acne. Objective: We previously performed screening test using cultured human sebocytes, and found that bilobetin had a potential for inhibiting lipid production. The aim of this study is to demonstrate the effects of bilobetin on IGF-1–induced lipogenesis in sebocytes. Methods: We pretreated simian virus 40 T (SV40T)-transformed sebocytes with bilobetin then stimulated with IGF-1. Effects of bilobetin on lipogenesis of sebocytes were examined by thin layer chromatography and Western blot. Results: Bilobetin markedly inhibited IGF-1– induced lipid production in sebocytes, especially in terms of production of squalene and wax ester. Supporting these results, bilobetin showed significant inhibitory effect on squalene synthase promoter activity. In addition, bilobetin significantly down-regulated lipogenic transcription factors such as sterol response element binding protein (SREBP)-1 and SREBP-2. To delineate the possible action mechanism, we investigated the effect of bilobetin on intracellular signaling. As a result, bilobetin inhibited IGF-1–induced phosphorylation of AKT. Conclusion: Together, these results suggest that bilobetin has an inhibitory potential on sebum production in sebocytes, being applicable for acne treatment.
참고문헌 (18)
- Zouboulis CC, "Beyond acne : current aspects of sebaceous gland biology and function", Rev Endocr Metab Disord, 17, pp.319~334 (2016)
- Shi VY, "Role of sebaceous glands in inflammatory dermatoses", J Am Acad Dermatol, 73, pp.856~863 (2015)
- Chen W, "Acne-associated syndromes : models for better understanding of acne pathogenesis", J Eur Acad Dermatol Venereol, 25, pp.637~646 (2011)
- 김효진, "Insulin-Like Growth Factor-1 Increases the Expression of Inflammatory Biomarkers and Sebum Production in Cultured Sebocytes", Annals of Dermatology, 29(1), pp.20~25 (2017), 대한피부과학회
- Krautheim A, "Acne : topical treatment", Clin Dermatol, 22, pp.398~407 (2004)
- Smith TM, "IGF-1induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase", Akt pathway, 2008, pp.128, 1286~1293
- Hwang YL, "Inhibitory effect of imperatorin on insulin-like growth factor-1-induced sebum production in human sebocytes cultured in vitro", Life Sci, 144, pp.49~53 (2016)
- Briançon-Scheid F, "HPLC separation and quantitative determination of biflavones in leaves from Ginkgo biloba", Planta Med, 49, pp.204~207 (1983)
- Im M, "Epigallocatechin-3-gallate suppresses IGF-I-induced lipogenesis and cytokine expression in SZ95 sebocytes", J Invest Dermatol, 132, pp.2700~2708 (2012)
- Melnik BC, "Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris", Exp Dermatol, 18, pp.833~841 (2009)
- Horton JD, "SREBPs : activators of the complete program of cholesterol and fatty acid synthesis in the liver", J Clin Invest, 109, pp.1125~1131 (2002)
- Kim HJ, "Sterol regulatory element-binding proteins(SREBPs)as regulators of lipid metabolism : polyunsaturated fatty acids oppose cholesterolmediated induction of SREBP-1 maturation", Ann N Y Acad Sci, 967, pp.34~42 (2002)
- Lynn DD, "The epidemiology of acne vulgaris in late adolescence", Adolesc Health Med Ther, 7, pp.13~25 (2016)
- Zouboulis CC, "Acne and sebaceous gland function", Clin Dermatol, 22, pp.360~366 (2004)
- Tóth BI, ""Sebocytes’makeup" : novel mechanisms and concepts in the physiology of the human sebaceous glands", Pflugers Arch, 461, pp.593~606 (2011)
- Picardo M, "Sebaceous gland lipids", Dermatoendocrinol, 1, pp.68~71 (2009)
- Saponara R, "Inhibition of cAMP-phosphodiesterase by biflavones of Ginkgo biloba in rat adipose tissue", J Nat Prod, 61, pp.1386~1387 (1998)
- Kou XH, "Bilobetin ameliorates insulin resistance by PKA-mediated phosphorylation of PPARα in rats fed a high-fat diet", Br J Pharmacol, 165, pp.2692~2706 (2012)